|
Market Closed -
Nasdaq
16:00:00 2026-02-09 EST
|
5-day change
|
1st Jan Change
|
|
473.12 USD
|
-2.52%
|
 |
-0.40%
|
-2.90%
|
|
01-26 |
United Therapeutics Corporation Announces Positive Results from Phase 1 Study of MiroliverELAP® in Patients with Acute Liver Failure
|
CI
| |
11-12 |
United Therapeutics Insider Sold Shares Worth $3,600,830, According to a Recent SEC Filing
|
MT
| |
11-06 |
United Therapeutics Insider Sold Shares Worth $3,488,423, According to a Recent SEC Filing
|
MT
| |
11-05 |
United Therapeutics Insider Sold Shares Worth $9,157,821, According to a Recent SEC Filing
|
MT
| |
11-04 |
United Therapeutics Insider Sold Shares Worth $3,554,592, According to a Recent SEC Filing
|
MT
| |
11-03 |
United Therapeutics Corporation Announces First Transplant in Expands Clinical Trial of UKidney in Patients with End-Stage Renal Disease
|
CI
| |
25-10-31 |
United Therapeutics Insider Sold Shares Worth $3,538,949, According to a Recent SEC Filing
|
MT
| |
25-10-30 |
United Therapeutics Insider Sold Shares Worth $4,953,760, According to a Recent SEC Filing
|
MT
| |
25-10-29 |
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on July 30, 2025.
|
CI
| |
25-10-29 |
United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
|
CI
| |
25-10-29 |
Earnings Flash (UTHR) United Therapeutics Posts Q3 EPS $7.16, vs. FactSet Est of $6.96
|
MT
| |
25-10-29 |
United Therapeutics Q3 Net Income, Revenue Rise
|
MT
| |
25-10-29 |
Earnings Flash (UTHR) United Therapeutics Corporation Reports Q3 Revenue $799.5M, vs. FactSet Est of $812.8M
|
MT
| |
25-10-29 |
United Therapeutics Q3 revenue misses estimates
|
RE
| |
25-10-22 |
United Therapeutics Insider Sold Shares Worth $3,399,650, According to a Recent SEC Filing
|
MT
| |
25-10-10 |
United Therapeutics Insider Sold Shares Worth $3,574,444, According to a Recent SEC Filing
|
MT
| |
25-10-08 |
United Therapeutics Insider Sold Shares Worth $3,610,769, According to a Recent SEC Filing
|
MT
| |
25-10-07 |
United Therapeutics Insider Sold Shares Worth $10,130,439, According to a Recent SEC Filing
|
MT
| |
25-10-06 |
United Therapeutics Insider Sold Shares Worth $3,583,612, According to a Recent SEC Filing
|
MT
| |
25-10-01 |
United Therapeutics Insider Sold Shares Worth $3,393,884, According to a Recent SEC Filing
|
MT
| |
25-09-29 |
United Therapeutics Insider Sold Shares Worth $3,436,630, According to a Recent SEC Filing
|
MT
| |
25-09-25 |
United Therapeutics Insider Sold Shares Worth $440,000, According to a Recent SEC Filing
|
MT
| |
25-09-19 |
United Therapeutics Corporation to Review Data from the Successful Teton-2 Pivotal Study of Nebulized Tyvaso®? in Idiopathic Pulmonary Fibrosis
|
CI
| |
25-09-02 |
A September Shiver on Wall Street
|  | |
25-09-02 |
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis
|
RE
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
